Critical need for appropriate mucosal sample collection to determine relational animal pharmacokinetic-pharmacodynamic models in HIV prevention.
作者信息
Marshall Leslie, Cummins James, Spiegel Hans, Turpin James, Veronese Fulvia, Kashuba Angela
机构信息
1 Preclinical Microbicide and Prevention Research Branch, Prevention Sciences Program, Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health , Bethesda, Maryland.
出版信息
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1398-400. doi: 10.1089/AID.2013.0142. Epub 2013 Aug 30.
Abstract
摘要
相似文献
1
Critical need for appropriate mucosal sample collection to determine relational animal pharmacokinetic-pharmacodynamic models in HIV prevention.迫切需要采集合适的黏膜样本，以确定HIV预防中相关动物的药代动力学-药效学模型。
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1398-400. doi: 10.1089/AID.2013.0142. Epub 2013 Aug 30.
2
Antiretroviral pharmacology in mucosal tissues.黏膜组织中的抗逆转录病毒药理学。
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2(0 2):S240-7. doi: 10.1097/QAI.0b013e3182986ff8.
3
Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.艾滋病预防中的药代动力学和药效学：现状与未来方向：美国国立过敏与传染病研究所艾滋病司（DAIDS）和比尔及梅琳达·盖茨基金会（BMGF）赞助的关于艾滋病预防中药代动力学（PK）/药效学（PD）的智库总结
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1418-27. doi: 10.1089/aid.2013.0122. Epub 2013 May 22.
4
Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues.简短通讯：马拉维若在黏膜组织中的抗HIV-1活性有限
AIDS Res Hum Retroviruses. 2016 Apr;32(4):334-8. doi: 10.1089/AID.2015.0315. Epub 2016 Jan 29.
5
Pharmacologic opportunities for HIV prevention.HIV 预防的药物治疗机会。
Clin Pharmacol Ther. 2010 Nov;88(5):598-609. doi: 10.1038/clpt.2010.189. Epub 2010 Sep 29.
6
Advances in HIV microbicide development.HIV 杀微生物剂研发进展。
Future Med Chem. 2011 Dec;3(16):2101-16. doi: 10.4155/fmc.11.153.
7
Animal models of antiretroviral prophylaxis for HIV prevention.用于 HIV 预防的抗逆转录病毒预防的动物模型。
Curr Opin HIV AIDS. 2012 Nov;7(6):505-13. doi: 10.1097/COH.0b013e328358e484.
8
A perspective on progress and gaps in HIV prevention science.对艾滋病病毒预防科学进展与差距的一种观点。
AIDS Res Hum Retroviruses. 2012 Nov;28(11):1373-8. doi: 10.1089/aid.2012.0277.
9
Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.拉替拉韦、埃替拉韦和多替拉韦在恒河猴血浆和黏膜分泌物中的药代动力学特征。
J Antimicrob Chemother. 2015 May;70(5):1473-81. doi: 10.1093/jac/dku556. Epub 2015 Jan 27.
10
Deducing Mucosal Pharmacokinetics and Pharmacodynamics of the Anti-HIV Molecule Tenofovir from Measurements in Blood.从血液测量推断抗 HIV 分子替诺福韦的黏膜药代动力学和药效学。
Sci Rep. 2019 Jan 14;9(1):82. doi: 10.1038/s41598-018-36004-z.
本文引用的文献
1
Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.艾滋病预防中的药代动力学和药效学：现状与未来方向：美国国立过敏与传染病研究所艾滋病司（DAIDS）和比尔及梅琳达·盖茨基金会（BMGF）赞助的关于艾滋病预防中药代动力学（PK）/药效学（PD）的智库总结
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1418-27. doi: 10.1089/aid.2013.0122. Epub 2013 May 22.
2
New generation humanized mice for virus research: comparative aspects and future prospects.新一代用于病毒研究的人源化小鼠：比较方面和未来前景。
Virology. 2013 Jan 5;435(1):14-28. doi: 10.1016/j.virol.2012.10.007.
3
Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice.人乳和抗逆转录病毒药物可显著降低 BLT 人源化小鼠经口腔感染 HIV-1 的风险。
PLoS Pathog. 2012;8(6):e1002732. doi: 10.1371/journal.ppat.1002732. Epub 2012 Jun 14.
4
Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice.BLT 人源化小鼠中的黏膜 HIV-1 传播和预防策略。
Trends Microbiol. 2012 Jun;20(6):268-74. doi: 10.1016/j.tim.2012.03.007. Epub 2012 Apr 12.
5
Generation of HIV latency in humanized BLT mice.在人源化 BLT 小鼠中生成 HIV 潜伏期。
J Virol. 2012 Jan;86(1):630-4. doi: 10.1128/JVI.06120-11. Epub 2011 Oct 19.
6
The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies.使用感染HIV的非人灵长类动物模型来评估抗病毒策略。
AIDS Res Hum Retroviruses. 2012 Jan;28(1):16-35. doi: 10.1089/aid.2011.0234. Epub 2011 Oct 19.
7
Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection.固相萃取和超灵敏 LC-MS/MS 检测法测定细胞基质中核苷类似物单、二、三磷酸。
J Pharm Biomed Anal. 2011 Sep 10;56(2):390-401. doi: 10.1016/j.jpba.2011.05.039. Epub 2011 Jun 6.
8
One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.将 1%的替诺福韦局部应用于人源化 BLT 小鼠，并按照 CAPRISA 004 实验设计使用，证明对阴道 HIV 感染具有部分保护作用，验证了 BLT 模型在评估新的杀微生物候选药物中的有效性。
J Virol. 2011 Aug;85(15):7582-93. doi: 10.1128/JVI.00537-11. Epub 2011 May 18.
9
Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.暴露前全身给予抗逆转录病毒药物可预防人源化 BLT 小鼠直肠和静脉内 HIV-1 的传播。
PLoS One. 2010 Jan 21;5(1):e8829. doi: 10.1371/journal.pone.0008829.
10
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.抗逆转录病毒暴露前预防可预防人源化BLT小鼠中HIV-1的阴道传播。
PLoS Med. 2008 Jan 15;5(1):e16. doi: 10.1371/journal.pmed.0050016.
Zotero 插件